Form 4: Protagonist Therapeutics CEO Gifts 5,000 Shares to Charity

Protagonist Therapeutics President and CEO, Dinesh V. Patel, Ph.D., reported a charitable donation of 5,000 shares of common stock on July 16, 2025.

Summary

• Dinesh V. Patel, Ph.D., who serves as President and CEO, and a Director of Protagonist Therapeutics, Inc. (PTGX), reported a change in his beneficial ownership.
• On July 16, 2025, Patel made a charitable donation of 5,000 shares of Protagonist Therapeutics common stock.
• The shares were gifted to a donor-advised fund, which intends to use them for charitable purposes.
• Following this transaction, Patel's beneficial ownership stands at 558,462 shares of Protagonist Therapeutics common stock.
• This total includes 557 shares that Patel acquired on March 7, 2025, through the Issuer's 2016 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The transaction reports a charitable donation of shares by the CEO, which is a non-sale disposition. The CEO retains a substantial beneficial ownership, and also recently acquired shares through an employee plan, indicating continued alignment and confidence.

Positives

• The charitable donation by the CEO demonstrates philanthropic engagement.
• The CEO maintains a substantial beneficial ownership of 558,462 shares, indicating continued alignment with shareholder interests.
• The recent acquisition of 557 shares via the Employee Stock Purchase Plan suggests ongoing confidence in the company's future.

Negatives

• The transaction represents a reduction in the CEO's direct beneficial ownership, albeit for charitable purposes.

Future Outlook

This Form 4 filing primarily reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Dinesh V. Patel, Ph.D., President and CEO, made a charitable donation of 5,000 shares of common stock.

Industry Context

This filing is an insider transaction report, which provides transparency into executive stock ownership changes within the biotechnology and pharmaceutical industry. It does not directly relate to broader industry trends but reflects individual executive activity.

Stakeholder Impact

• Shareholders: The charitable gift represents a minor reduction in the CEO's direct ownership, but his continued significant holding of 558,462 shares maintains strong alignment with shareholder interests.

Key Dates

Recommendation

Keywords

Protagonist Therapeutics, PTGX, Dinesh V. Patel, CEO, charitable donation, insider transaction, Form 4, beneficial ownership, employee stock purchase plan